Further investigation into the above upstream regulators and the small molecules associated with the microbial metabolites which enhance the regulatory function of CD103+ B cells may prove very valuable in devising future therapies to prevent autoimmune disease development. This evidence concerns the gene ITGAE and autoimmune disease.